Lipid Management

Study Targets Right Alirocumab Dosage for Hypercholesterolemia Patients

August 03, 2020


The most common adverse events were injection-site reactions and headaches.

Model Accurately Predicts Benefit of Lipid-Lowering Therapies

July 30, 2020


The model can simulate treatment benefit over time with time-varying low-density lipoprotein cholesterol.

Treating Combined High Lipoprotein, Inflammation Reduces MACE Risks

July 20, 2020


A secondary ACCELERATE assessment shows a particular set of patients who may benefit from Lp(a)-lowering novel agents.

National Lipid Association Gives Statement on Dyslipidemia Genetic Testing

July 15, 2020


The practice of genetic testing has been useful in clinically addressing found cases of familial hypercholesterolemia, among other conditions, but no clinical practice guidelines currently exist for testing patients with suspected hereditary dyslipidemia.

Concierge Medicine and Cardiac Care During COVID-19

July 15, 2020


What does personalized outpatient care look like for a cardiology institute during the pandemic?

Gestational Hypertension Increases Risk of CVD, CHD But Not Thromboembolism

June 25, 2020


A new systematic review and meta-analysis is shedding light on the impact gestational hypertension can have on future risk of cardiovascular diseases.

HDL Cholesterol Not As Useful for Predicting MI in Minority Patients

June 23, 2020


While often referred to as "Good cholesterol" new research suggests HDL measurements do little for predicting risk of heart attack in Black patients

Tai Chi Improves Mental Well-Being of Patients with Cardiovascular Disease

June 09, 2020


A new study from the University of Arizona is shedding light on the psychological impact of Tai Chi in patients with cardiovascular disease.

Blood Pressure Treatment Adherence Reduces Mortality, Regardless of Frailty

June 08, 2020


A new analysis examines impact of treatment adherence in more than 1.2 million patients.

FDA Approves Ticagrelor DAPT for Patients Without CVD, Stroke History

June 01, 2020


The expanded indication is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy in those with a high risk, but no history of heart attack or stroke.